Overall response at day 28 after the initiation of second line therapy for GVHD. ORR (CR or PR) shown for patients according to (A) MAP (low vs high), (B) choice of second-line therapy (ruxolitinib vs no-ruxolitinib), and (C) both MAP (low vs high) and second line therapy group (ruxolitinib vs no-ruxolitinib). Rux, ruxolitinib.